NovaBay Pharmaceuticals Closes DERMAdoctor Acquisition
November 08 2021 - 6:50AM
Business Wire
Company to hold third quarter 2021 earnings
call on November 11 and will discuss plans for the combined
companies
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
the closing of the previously announced acquisition of DERMAdoctor,
LLC. The Company also announced that it will report financial
results for the third quarter 2021 on Thursday November 11, 2021
and will hold an investment community conference call that day
beginning at 4:30 p.m. Eastern time.
“Now that we have officially closed on the acquisition, it is
time to start realizing synergies and growing our combined
businesses. On our conference call later this week we will discuss
the many benefits we see from the DERMAdoctor acquisition in
addition to detailing our third quarter financial results,” said
Justin Hall, NovaBay CEO. “The timing of this earnings call allows
us to recap recent accomplishments and share some detail on our
strategic vision going forward.”
The Company was advised by Two Roads Advisors LLC, a boutique
investment bank led by John Z. Fang and Rob Cooper, in the
acquisition of DERMAdoctor.
Date/Time:
Thursday, November 11, 4:30 p.m. ET / 1:30
p.m. PT
Pre-Registration:
Participants can pre-register for the
conference call here:
Callers who pre-register will be given a
conference passcode and unique PIN to gain immediate access to the
call and bypass the live operator. Participants may pre-register at
any time, including up to and after the call start time.
Dial In:
Those who choose not to pre-register can
access the live conference call by dialing the following and
requesting the NovaBay Pharmaceuticals call:
866-777-2509 from within the U.S.
412-317-5413 from outside the U.S.
The live webcast of the conference call also will be available
at http://novabay.com/investors/events. A replay of the call will
be available beginning two hours after its completion through
December 2, 2021 by dialing 877-344-7529 from within the U.S.,
855-669-9658 from Canada or 412-317-0088 from outside the U.S., and
entering conference ID 10161592. The webcast will also be archived
at http://novabay.com/investors/events.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor will there be any sales of
these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such jurisdiction.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is pharmaceutical company that
develops and sells scientifically created and clinically proven
consumer products for the eyecare and skincare markets. Avenova® is
the most prescribed antimicrobial lid and lash spray and CelleRx®
is a breakthrough product in the beauty category. In November 2021,
NovaBay acquired DERMAdoctor, LLC, a company commercializing more
than 30 dermatologist-developed skincare products sold through
major traditional retailers, digital beauty retailers and online to
international markets through a network of international
distribution and retailers.
Forward-Looking Statements
Matters set forth in this press release or discussed on the
investment community conference call may be forward-looking within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995, including statements
about the commercial progress, potential opportunities for revenue
accretion and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies and current product offerings, potential future product
offerings including through strategic acquisitions such as the
acquisition of DERMAdoctor, LLC, expanded access to our products,
and any future revenue that may result from selling these products,
as well as generally the Company’s expected future financial
results. These statements involve known and unknown risks,
uncertainties and other factors that may cause actual results or
achievements to be materially different and adverse from those
expressed in or implied by the forward-looking statements. Factors
that might cause or contribute to such differences include, but are
not limited to, risks and uncertainties relating to the size of the
potential market for our products, the integration of DERMAdoctor’s
business into the Company’s business, the possibility that the
available market for the Company’s products will not be as large as
expected, the Company’s products will not be able to penetrate one
or more targeted markets, and revenues will not be sufficient to
meet the Company’s cash needs. Other risks relating to NovaBay’s
business, including risks that could cause results to differ
materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay’s latest Form 10-Q/K
filings and Preliminary Proxy Statement filing with the Securities
and Exchange Commission, especially under the heading “Risk
Factors.” The forward-looking statements in this release speak only
as of this date, and NovaBay disclaims any intent or obligation to
revise or update publicly any forward-looking statement except as
required by law.
Socialize and Stay informed on
NovaBay’s progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211108005369/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2024 to May 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024